Skip to main content
National Science Foundation Grant
19, Oct 2020

Plexision Awarded Competitive Grant from the National Science Foundation for COVID-19 Immunity Test Development

Plexision has been awarded a National Science Foundation (NSF) Phase 1 Small Business Innovation Research Grant. The grant was awarded to Plexision for its COVID-19 immunity test. The blood test measures cell-mediated immunity to the SARS-CoV-2 coronavirus. It allows medical providers to assess the risk of COVID-19 infection, the blood test also identifies if a patient is at risk for a severe infection. Now more than ever medical providers across the globe are in need of the necessary tools to combat this virus and assist in patient treatment plans, Plexision's technology is doing just that! By allowing medical professionals to get the upper hand on a patient's infection risk physicians will now be able to recommend appropriate preventative measures and if needed plan accordingly to limit progression in those already infected.

To read more please visit the following link: www.businesswire.com

About

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.

Contact